Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1995-7-27
|
| pubmed:abstractText |
The incidence of factor VIII inhibitor was studied in a cohort of 56 previously untreated patients with severe hemophilia A (factor VIII below 1 U/dl). They received only one brand of highly purified factor VIII concentrate (HPSD-VIII) prepared by conventional chromatography with a solvent-detergent step for viral inactivation. Follow-up since the first infusion of HPSD-VIII was from 1 to 76 months (mean = 29) and cumulative exposure days (CED) from 1 to over 100 (median = 26). Five patients (9%) developed an inhibitor after 6 to 19 CED, only one being a high responder (2%), showing a low incidence of inhibitor compared with previous studies using high purity plasma-derived or recombinant products.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0340-6245
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
73
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
215-8
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7792732-Child, Preschool,
pubmed-meshheading:7792732-Factor VIII,
pubmed-meshheading:7792732-Follow-Up Studies,
pubmed-meshheading:7792732-Hemophilia A,
pubmed-meshheading:7792732-Humans,
pubmed-meshheading:7792732-Infant,
pubmed-meshheading:7792732-Infant, Newborn,
pubmed-meshheading:7792732-Retrospective Studies,
pubmed-meshheading:7792732-Treatment Outcome
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
|
| pubmed:affiliation |
Hemophilia Center of Tours, France.
|
| pubmed:publicationType |
Journal Article
|